Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of golidocitinib added to chemotherapy for peripheral T-cell lymphoma with suboptimal interim response to first-line therapy
ChiCTR2600131819Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of golidocitinib in peripheral T-cell lymphoma (PTCL), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Objective response rate and Complete response rate. Started Sep 2025; status: recruiting.
02
Drugs
golidocitinib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on ChiCTR2600131819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131819.